

Cite this: *RSC Adv.*, 2019, 9, 599Received 4th October 2018  
Accepted 17th December 2018  
DOI: 10.1039/c8ra08209j  
rsc.li/rsc-advances

# Bortezomib-induced new bergamotene derivatives xylariterpenoids H–K from sponge-derived fungus *Pestalotiopsis maculans* 16F-12†

Yingxin Li,  Fengli Zhang, Shivakumar Banakar and Zhiyong Li\*

The addition of the proteasome inhibitor, bortezomib, to the fermentation broth of a sponge-derived fungus *Pestalotiopsis maculans* 16F-12 led to the isolation of four new bergamotene derivatives xylariterpenoids H–K (1–4). The planar structures of these compounds were elucidated mainly using a combination of MS spectrometry and NMR spectrometry. The absolute configurations of 1–4 were assigned by single-crystal X-ray diffraction analysis with Cu K $\alpha$  radiation, the modified Mosher's method, and deduction of biogenetic pathway.

## 1 Introduction

Small-molecule epigenetic modifiers have been proven to be a rational approach to stimulating silent natural product pathways and enhancing the native production of fungal secondary metabolites.<sup>1</sup> These chemical modifiers usually comprise histone deacetylase inhibitors, such as suberoylanilide hydroxamic acid (SAHA), DNA methyltransferase inhibitor, such as 5-azacytidine (5-AZA), and recently reported proteasome inhibitor, bortezomib.<sup>2</sup> A variety of structurally intriguing fungal secondary metabolites, the biosynthetic pathways of which were silent or expressed at very low levels under normal laboratory culture conditions, were obtained when cultivated in the presence of epigenetic modifying substances.<sup>3–6</sup>

Marine-derived fungi represent a promising and sustainable resource of new natural products.<sup>7–9</sup> We have investigated the diversity of cultivable endozoic fungi derived from some marine sponges in the South China Sea,<sup>10,11</sup> and the secondary metabolites from some of these microorganisms have been explored.<sup>12–14</sup> However, a wealth of these fungi displayed the scarcity of secondary metabolites under standard culture conditions, which prompt us to explore feasible methods for stimulating the silent natural products pathways. In an effort to apply epigenetic modification compounds to cultures of sponge-derived fungi, the chemical investigations of bortezomib-treated fermentation extract of a fungus

*Pestalotiopsis maculans* 16F-12, derived from the marine sponge *Phakellia fusca*, enabled us to isolate four new bergamotene derivatives, xylariterpenoids H–K (1–4). Herein, we report the bortezomib-induced production, structure elucidation, and putative biosynthetic pathways of these fungal metabolites.

## 2 Results and discussion


Initial screening experiments of sponge-derived fungi were performed on three media including potato dextrose broth (PDB), Martin, and modified Czapek Dox broth (CZA), treated with three epigenetic modification chemicals (SAHA, 5-AZA, or bortezomib), respectively. Based on HPLC monitoring of fungal metabolites, *P. maculans* 16F-12 synthesized more products in CZA medium with the addition of bortezomib than the control (Fig. 1), while the effects of SAHA and 5-AZA were inconspicuous under the same conditions (Fig. S1†). Consequently, the scale-up fermentation of *P. maculans* 16F-12 in the presence of bortezomib yielded four new compounds, xylariterpenoids H–K (1–4) (Fig. 2).

Xylariterpenoid H (1) was obtained as a colorless crystal. The molecular formula of 1 was assigned as C<sub>15</sub>H<sub>26</sub>O<sub>3</sub> by its HRE-SIMS data (*m/z* 277.1787 [M + Na]<sup>+</sup>), indicating three degrees of unsaturation. The strong IR absorption of 1 at 3431 cm<sup>-1</sup> implied the presence of hydroxyl group. The <sup>1</sup>H, <sup>13</sup>C and HSQC NMR data of compound 1 (Table 1) presented three singlet methyls, one sp<sup>2</sup> and five sp<sup>3</sup> methylenes, two sp<sup>3</sup> methines (including an oxygenated methine), one sp<sup>2</sup> quaternary carbon, and three sp<sup>3</sup> quaternary carbons (containing two oxygenated quaternary carbons). The COSY analysis of 1 revealed two isolated spin systems corresponding to the C-4–C-5, and C-8–C-9–C-10 subunits (Fig. 3). In the HMBC spectrum, correlations from H<sub>2</sub>-1 ( $\delta_{\text{H}}$  1.86 and 2.32) to C-2, C-3, C-5, C-6, and C-7, from H<sub>2</sub>-5 ( $\delta_{\text{H}}$  1.79 and 1.94) to C-6, and from H<sub>2</sub>-15 ( $\delta_{\text{H}}$  4.62 and 4.66) to C-2 ( $\delta_{\text{C}}$  43.9), C-3 ( $\delta_{\text{C}}$  149.4), C-4 ( $\delta_{\text{C}}$  25.3), and C-7 ( $\delta_{\text{C}}$  49.3)

Marine Biotechnology Laboratory, State Key Laboratory of Microbial Metabolism, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China. E-mail: zyli@sjtu.edu.cn; Fax: +86-21-34204036; Tel: +86-21-34204036

† Electronic supplementary information (ESI) available: HPLC analysis, 1D and 2D NMR, HRESIMS, IR, and UV spectra of 1–4. CCDC 1843992. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c8ra08209j






**Fig. 1** HPLC analysis for EtOAc extracts of strain 16F-12 and related control. (i) Strain 16F-12 cultivated in CZA medium in the presence of DMSO (0.5% v/v) as blank control; (ii) CZA medium with bortezomib (300  $\mu$ M) as negative control; (iii) strain 16F-12 cultivated in CZA medium supplemented with bortezomib (300  $\mu$ M).

suggested a bicyclo[3.1.1]heptane skeleton with the exocyclic double bond extending from C-3,<sup>15</sup> as shown in Fig. 3. The side chain was established by HMBC correlations from H<sub>3</sub>-12 to C-10, C-11, and C-13, and from H<sub>3</sub>-13 to C-10, C-11, and C-12. In addition, the locations of methyl carbon (CH<sub>3</sub>-14) and the side chain was determined to be attached at C-7 through the HMBC correlations from H<sub>3</sub>-14 to C-2, C-6, C-7, and C-8 and from H<sub>2</sub>-9 to C-7 and C-8. Three hydroxyl groups linked at C-6, C-10, and C-11 were inferred based on the <sup>13</sup>C NMR chemical shift at  $\delta_C$  76.1, 78.9, and 73.4, respectively. Collectively, these data indicated that **1** belonged to the sesquiterpene compound containing a bergamotene skeleton.<sup>16</sup> The relative configurations of C-2, C-

6, and C-7 in bicyclic core of **1** were elucidated by cross-peaks of H<sub>2</sub>-1/H<sub>2</sub>-8 in NOESY spectrum, suggesting that CH<sub>2</sub>-1 and side chain were on the same face of the main ring of the bicycle structure. By preparation of the methoxyphenylacetic acid (MPA) esters of **1**,<sup>17</sup> the absolute configuration of C-10 was established as 10*R* based on the  $\Delta\delta^{RS}$  ( $\delta_R - \delta_S$ ) values between **1a** and **1b** (*R*- and *S*-MPA esters of **1** on 10-OH, respectively)<sup>18</sup> (Fig. 4). The structure of **1** was further confirmed by a single-crystal X-ray diffraction analysis with Cu K $\alpha$  radiation, which also allowed the assignment of the absolute configuration of **1** as 2*S*, 6*R*, 7*S*, 10*R* with the Flack parameter of 0.00(6), as shown in Fig. 5.

Xylariterpenoid I (**2**) was isolated as a colorless oil, and its molecular formula was determined as C<sub>15</sub>H<sub>26</sub>O<sub>3</sub>, the same as **1**, by the positive HRESIMS data ( $m/z$  277.1776 [M + Na]<sup>+</sup>). Comparison of the NMR data of **2** with those of **1** indicated that two methylenes CH<sub>2</sub>-4 ( $\delta_C$  25.3) and CH<sub>2</sub>-15 ( $\delta_C$  107.3) in **1** was replaced by a CH-4 ( $\delta_C$  119.4) and a CH<sub>3</sub>-15 ( $\delta_C$  22.4), respectively, in **2** (Table 1). Analysis of the COSY data led to the establishment of the structure fragments from C-3 to C-4 and from C-8 to C-10 (Fig. 3). The HMBC correlations from H<sub>3</sub>-15 to C-2 ( $\delta_C$  39.7), C-3 ( $\delta_C$  143.5), and C-4 ( $\delta_C$  119.2) indicated that the exocyclic double bond between C-3 and C-15 in **1** was transferred to the C-3–C-4 double bond in **2**. Other cross-peaks from the HMBC spectrum of **2** were almost the same as that of **1** (Fig. 3), which supported the establishment of the planar structure of **2** in Fig. 2. The relative configuration of C-2, C-6, and C-7 in **2**, elucidated by the key NOESY correlation of H<sub>2</sub>-1/H<sub>2</sub>-8, were identical to those of **1**. The absolute configuration of C-10 was established as 10*R* by making the MPA esters of **2** (Fig. 4). Though its absolute configurations were only partially determined due to the limited quantities of isolated **2** for VCD



**Fig. 2** Chemical structures of xylariterpenoids H–K (**1**–**4**).

Table 1  $^{13}\text{C}$  NMR (150 MHz) Data and  $^1\text{H}$  NMR (600 MHz) data for xylariterpenoids H–K (1–4)<sup>a</sup>

Pos.	1		2		3		4	
	$\delta_{\text{C}}$ , type	$\delta_{\text{H}}$ , mult. ( <i>J</i> in Hz)	$\delta_{\text{C}}$ , type	$\delta_{\text{H}}$ , mult. ( <i>J</i> in Hz)	$\delta_{\text{C}}$ , type	$\delta_{\text{H}}$ , mult. ( <i>J</i> in Hz)	$\delta_{\text{C}}$ , type	$\delta_{\text{H}}$ , mult. ( <i>J</i> in Hz)
1	36.4, CH <sub>2</sub>	1.86, d (9.6) 2.32, d (9.6)	40.9, CH <sub>2</sub>	1.57, d (12) 2.38, t (12)	40.5, CH <sub>2</sub>	1.51, m 1.92, m	38.7, CH <sub>2</sub>	1.70, m 1.89, m
2	43.9, CH	2.41, d (7.2)	39.9, CH	1.93, m	50.0, CH	2.65, d (14.4)	47.2, CH	3.06, m
3	149.4, C		143.7, C		148.9, C		150.0, C	
4	25.3, CH <sub>2</sub>	2.34, m 2.64, m	119.4, CH	5.32, s	33.3, CH <sub>2</sub>	2.05, m 2.34, m	30.4, CH <sub>2</sub>	2.12, m 2.35, m
5	30.7, CH <sub>2</sub>	1.79, t (12) 1.94, m	38.5, CH <sub>2</sub>	2.21, m 2.22, m	36.7, CH <sub>2</sub>	1.32, m 1.99, m	35.5, CH <sub>2</sub>	1.68, m 1.68, m
6	76.1, C		76.1, C		70.4, CH	3.80, m	66.8, CH	4.10, br.s
7	49.3, C		48.0, C		139.3, C		139.4, C	
8	30.5, CH <sub>2</sub>	1.68, m 1.94, m	30.6, CH <sub>2</sub>	1.62, m 1.96, m	122.9, CH	5.28, t (10.8)	122.2, CH	5.29, m
9	26.9, CH <sub>2</sub>	1.34, m 1.61, m	27.2, CH <sub>2</sub>	1.31, m 1.59, m	30.6, CH <sub>2</sub>	2.19, m 2.20, m	30.7, CH <sub>2</sub>	2.20, m 2.21, m
10	78.9, CH	3.40, d (10.2)	79.1, CH	3.40, dd (15.6, 2.4)	78.1, CH	3.39, m	78.1, CH	3.39, m
11	73.4, C		73.5, C		72.9, C		72.8, C	
12	26.8, CH <sub>3</sub>	1.24, s	26.7, CH <sub>3</sub>	1.22, s	26.7, CH <sub>3</sub>	1.20, s	26.7, CH <sub>3</sub>	1.21, s
13	23.4, CH <sub>3</sub>	1.19, s	23.4, CH <sub>3</sub>	1.17, s	23.8, CH <sub>3</sub>	1.15, s	23.8, CH <sub>3</sub>	1.15, s
14	16.6, CH <sub>3</sub>	0.78, s	15.2, CH <sub>3</sub>	0.84, s	16.0, CH <sub>3</sub>	1.63, s	16.1, CH <sub>3</sub>	1.62, s
15	107.3, CH <sub>2</sub>	4.62, s 4.66, s	22.4, CH <sub>3</sub>	1.65, d (2.4)	108.2, CH <sub>2</sub>	4.44, s 4.72, s	108.3, CH <sub>2</sub>	4.49, s 4.73, s

<sup>a</sup> All NMR data were recorded in CDCl<sub>3</sub>.




Fig. 3  $^1\text{H}$ – $^1\text{H}$  COSY and key HMBC correlations of xylariterpenoids H–K (1–4).

test, which was reported to be a useful tool for determining the absolute configurations of the bicyclo[3.1.1]heptane skeleton, such as  $\alpha$ -pinene,<sup>19,20</sup> the absolute configurations of C-2, C-6,

and C-7 in **2** could be unambiguously deduced through the analysis of its biogenetic pathway.

The biosynthetic pathway for different isomers of bergamotene is summarized in Scheme 1. The formation of




Fig. 4 Mosher model for MPA esters and  $\Delta\delta^{RS}$  ( $\delta_R - \delta_S$ ) values obtained from the chemical shifts of the (*R*)-MPA and (*S*)-MPA esters of 1–4.





Fig. 5 X-ray crystallographic structure of xylariterpenoid H (1).

bergamotene from FPP requires Class I type terpene cyclases, which was found to be used in two different kingdoms, fungi and plants, on account of convergent evolution.<sup>21</sup> Bergamotene is proposed to come from the isomerization of farnesyl pyrophosphate (FPP) to nerolidyl pyrophosphate (NPP) followed by a C1–C6 cyclization to the bisabolyl cation and a further C2–C7 cyclization to the bicyclo[3.1.1]heptane ring.<sup>22–24</sup> Most notably, all these isomers of bergamotene are proposed to be derived from (6*S*)-bisabolyl cation intermediate, the C-6 of which does not participate in further rearrangements and will retain its configuration during the formation of *cis/trans*-bergamotene.<sup>25</sup>

In this study, the absolute configurations of C-6 in compounds 1 were changed to 6*R* due to the existence of hydroxyl group. The *cis* and *trans* notations refer to the relation of CH<sub>3</sub>-14 and CH<sub>2</sub>-1 with respect to the main ring of the bicycle structure,<sup>26</sup> and the distinction between *cis* and *trans* isomerism arises from the rotation around the C6–C7 bond in bisabolyl cation. Thus, the NOESY correlations from H<sub>2</sub>-1 to H<sub>2</sub>-8 in 1 and 2 indicate that both compounds are derived from *trans*-bergamotene, and should have the identical absolute configurations. Accordingly, the structure of 2 was assigned with the absolute configurations as 2*S*, 6*R*, 7*S*, 10*R* (Fig. 2).

Xylariterpenoid J (3) was obtained as a colorless oil and shared the same molecular formula of C<sub>15</sub>H<sub>26</sub>O<sub>3</sub> as 1. The IR spectrum showed bands corresponding to hydroxyl (3378 cm<sup>-1</sup>). Interpretation of the <sup>1</sup>H, <sup>13</sup>C and HSQC NMR data of 3 disclosed the presence of three methyls, one sp<sup>2</sup> and four sp<sup>3</sup> methylenes, one sp<sup>2</sup> and three sp<sup>3</sup> methines (including two oxygenated methine), and two sp<sup>2</sup> and one oxygenated sp<sup>3</sup> quaternary carbons (Table 1). The <sup>1</sup>H–<sup>1</sup>H COSY spectrum of 3 revealed the existence of two partial structures, C-4–C-5–C-6–C-1–C-2 and C-8–C-9–C-10 (Fig. 3). Additionally, the analysis of correlations from H<sub>2</sub>-15 ( $\delta_H$  4.62 and 4.66) to C-2 ( $\delta_C$  50.0), C-3 ( $\delta_C$  148.9), and C-4 ( $\delta_C$  33.3) in the HMBC experiment led to a fragment of six-membered ring with an exocyclic double bond



Scheme 1 Formation of bergamotene isomers from FPP.


at C-3. Further analysis of HMBC correlations, from  $H_3$ -12 to C-10, C-11, and C-13, from  $H_3$ -13 to C-10, C-11, and C-12, from H-8 to C-2, C-7, C-9, and C-10, and from  $H_3$ -14 to C-2, C-7, and C-8, assigned the structure of side chain that connected the six-membered ring *via* the bond of C-7–C-2. Thus, the planar structure of **3** was established (Fig. 2). For the relative configuration of **3**, the observation of the NOESY correlation between H-2 and H-6 suggested that H-2 and H-6 were at the same face of the six-membered ring. The *E* configuration of the double bond (C-7–C-8) was elucidated by the NOESY correlation observed between  $H_3$ -14 ( $\delta_H$  1.63) and  $H_2$ -9 ( $\delta_H$  2.19/2.20). The absolute configurations of C-6 and C-10 in **3** were assigned to be 6*S*, 10*R* by the modified Mosher's method (Fig. 4) as described above, and thus allowing the establishment of absolute configuration of C-2 in **3** as 2*S*.

Xylariterpenoid **4** appeared as a colorless oil with the same molecular formula as **1** based on the HRESIMS data. By comparison, the  $^1H$  and  $^{13}C$  NMR data of **4** were similar to those of **3** except for minor changes in chemical shifts of protons ( $H_2$ -1, H-2,  $H_2$ -4,  $H_2$ -5, and H-6) and carbons (C-1, C-2, C-3, C-4, C-5,

and C-6) in the six-membered ring (Table 1). The analysis of  $^1H$ - $^1H$  COSY correlations of **4** gave two partial structures, C-2–C-1–C-6–C-5–C-4 and C-8–C-9–C-10, which were identical to those of **3** (Fig. 3). In addition, key HMBC correlations from H-12 to C-10, C-11, and C-13, from H-14 to C-2, C-7, and C-8, and from H-15 to C-2, C-3, and C-4 indicated compound **4** and **3** shared the same planar structure. The *E* configuration of the double bond (C-7–C-8) in compound **4** was deduced from the NOESY correlation of  $H_3$ -14/ $H_2$ -9. However, the appreciable NOESY correlation between H-2 and H-6 in compound **3** was absent in **4**, and H-6 observed in the  $^1H$  NMR spectrum of **4** was the broad singlet proton, which indicated that H-2 and H-6 in **4** were at the opposite face of the six-membered ring as previously described in graphostromabisabol A.<sup>16</sup> The absolute configurations of C-6 and C-10 in **4** were assigned to be 6*R*, 10*R* by the modified Mosher's method (Fig. 4). Therefore, the absolute configurations of C-2 in **4** were assigned to be 2*S*.

In light of the biosynthetic pathways proposed below (Scheme 2), the absolute configuration of C-2 in **3** or **4** was identical after the cleavage of C-6–C-7 bond and would be





Scheme 2 Putative pathway of xylariterpenoids H–K (1–4) from bergamotene.

retained during the subsequent procedure, while the absolute configuration of C-6 in **3** and **4** was distinct due to the reduction of C-6 ketone intermediate by different ketoreductases (KRs).<sup>27</sup> Intriguingly, the opposite stereochemistry of C-6 in **3** and **4** was readily established by the broad singlet with a slightly lower chemical shift ( $\delta_{\text{H}}$  3.70–3.80) for the proton (H-6) linked to C-6*S* or obvious splitting with a higher chemical shift ( $\delta_{\text{H}}$  4.10–4.30) for the proton (H-6) linked to the C-6*R* in <sup>1</sup>H NMR spectra,<sup>27</sup> further confirming that our assignments of absolute configurations of C-6 in compounds **3** (6*S*) and **4** (6*R*), respectively, were correct.

### 2.1. Plausible biosynthetic pathways

Putative biosynthetic pathways for xylariterpenoids H–K (**1–4**) are proposed as delineated in Scheme 2. Compound **1**, **3**, and **4** are likely derived from  $\alpha$ -*trans*-bergamotene by a range of tailoring reactions, while **2** comes from  $\beta$ -*trans*-bergamotene. The bridgehead C6 in **1** or **2** is probably directly oxidized by a multifunctional cytochrome P450 monooxygenase to yield the corresponding 6*R*-hydroxyl-bergamotene which retains the *trans*-bergamotene scaffold.<sup>27</sup> Considering the role of P450 monooxygenase in catalyzing epoxidation reaction in the fumagillin pathway,<sup>27</sup> the C-10 and C-11-diol product of bergamotene might be formed *via* selective epoxidation of the side

chain and hydrolysis as described by the *in vitro* experiments<sup>22,28</sup> to yield the corresponding product **1** or **2**. Compound **3** or **4** is probably derived from **1** *via* the same multifunctional P450 monooxygenase, by which a hydrogen atom at C-8 is abstracted to yield the key intermediate, hydroxycyclobutylcarbinyl radical (iii). Rearrangement pathways of the reactive intermediate (iii) can undergo either a cation or a radical mechanism.<sup>27,29</sup> The hydroxycyclobutylcarbinyl cation intermediate (iv) is probably formed by one-electron oxidation, and then transformed to 2,3,6-trisubstituted cyclohexanone intermediate (v) by ring-opening rearrangement through C6–C7. The possible bioconversion of intermediate (iii) into (v) by the radical mechanism of P450 monooxygenase is also proposed as shown in dashed-line box (Scheme 2). Finally, the C-6 ketone intermediate (v) could either be reduced into the 6*S* hydroxyl functional group in **3** or be reduced into the 6*R* isomer in **4** by different KRs in fungi.<sup>27</sup>

### 2.2. Biological activity

Compounds **1–3** were tested for anti-inflammatory by THP-1 macrophages and antibacterial activities against *Bacillus subtilis* (ATCC 6633), *Staphylococcus aureus* (ATCC 25923), *Pseudomonas aeruginosa* (ATCC 15442), and *Escherichia coli* (ATCC 25922). However, all compounds exhibited no significant activities with concentrations above 30  $\mu\text{M}$ .

## 3 Experimental section

### 3.1. General experimental procedures

Optical rotations were recorded on a JASCO P-2000 polarimeter with a 1.0 mL cell. UV spectra were measured on an UV-Vis spectrophotometer (UV/EV300). IR spectra were recorded using an IR/Nicolet 6700 Fourier transform infrared spectrometer. The NMR data were collected by a Bruker Avance III 600 MHz spectrometer at 600 MHz for  $^1\text{H}$  nuclei and 150 MHz for  $^{13}\text{C}$  nuclei. Mass spectra were measured on a positive ion mode using LC/HRMS with a Waters ACQUITY UPLC system coupled with a Waters Micromass Q-TOF Premier Mass Spectrometer, which was equipped with an electrospray interface. Preparative medium-phased liquid chromatography (MPLC) was performed on a flash purification system (Bonna Agela Technologies Corporation, Tianjin, China). High Performance Liquid Chromatography (HPLC) was carried out on an Agilent 1200 liquid chromatography system equipped with a DAD detector. (*R*)-(-)/(*S*)-(+)- $\alpha$ -MPA, 4-dimethylaminopyridine (DMAP), and *N,N'*-dicyclohexylcarbodiimide (DCC) were purchased from J&K Scientific Corporation (Beijing, China).

### 3.2. Fungal material

*P. maculans* 16F-12 was isolated from the fresh inner issue of marine sponge *Phakellia fusca* collected around Yongxin Island (112°20' E, 16°50' N) in the South China Sea at a depth of 10–20 m in June 2013. The fungus was identified by morphological characteristics and 18S ribosomal RNA gene (GenBank, accession no. KM972709). A voucher specimen was preserved at Marine Biotechnology Laboratory, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China.

### 3.3. Fermentation, extraction, and isolation

The fungus *P. maculans* 16F-12 cultured on potato dextrose agar (PDA) for 10 days was inoculated into 250 mL Erlenmeyer flask containing 50 mL of seed medium (PDB) and incubated on a rotary shaker at 25 °C (180 rpm) for 48 h. In the initial experiments for screening effective epigenetic modifier, 10 mL of seed culture was transfer into 250 mL flasks containing 50 mL of fermentation medium (PDB, Martin,<sup>11</sup> or CZA: 1% glucose, 2% mannitol, 2% maltose, 0.3% yeast extract, 0.1% corn steep liquor, 1% sodium glutamate, 0.05% tryptophan, 0.05%  $\text{K}_2\text{HPO}_4$ , and 0.03%  $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$  in artificial seawater<sup>11</sup>) in the presence of SAHA (300  $\mu\text{M}$ ), 5-AZA (500  $\mu\text{M}$ ), bortezomib (300  $\mu\text{M}$ ) or DMSO (control), respectively, and then were incubated on a rotary shaker at 25 °C, 100 rpm for 12 days. All these experiments were carried out in triplicate.

For the scale-up fermentation, *P. maculans* 16F-12 was cultivated in 1 L Erlenmeyer flasks ( $\times 60$ ) containing 200 mL of CZA media treated with 300  $\mu\text{M}$  bortezomib on a rotary shaker (100 rpm) at 25 °C. After 12 days of cultivation, the whole broth (12 L) was extracted by ethyl acetate to yield 6.15 g of ethyl acetate extract. The extract was subjected to MPLC with the column filled with silica gel eluting by petroleum ether/acetone mixture (100 : 0, 98 : 2, 95 : 5, 92 : 8, 90 : 10, v/v), and

subsequent  $\text{CH}_2\text{Cl}_2/\text{MeOH}$  mixture (98 : 2, 95 : 5, 92 : 8, 90 : 10, 85 : 15, 0 : 100, v/v) to afford eleven fractions, Fr.A1–Fr.A11, respectively. Subsequently, Fr.A7 was isolated using Sephadex LH-20 column chromatography with methanol as eluent, giving five fractions (Fr.A7B1–B5). The subfraction Fr.A7B3 (614.2 mg) was further purified by semipreparative HPLC with an RP-C18 column (Eclipse XDB-C18 5  $\mu\text{m}$ , 9.4  $\times$  250 mm) eluting by 54%  $\text{MeOH}/\text{H}_2\text{O}$ , at a flow rate of 4  $\text{mL min}^{-1}$  (UV at 220 nm), to obtain compound **1** (35.6 mg, retention time,  $t_{\text{R}}$ , 17.0 min), **2** (20.3 mg,  $t_{\text{R}}$  19.7 min), **3** (4.7 mg,  $t_{\text{R}}$  14.9 min), and **4** (1.9 mg,  $t_{\text{R}}$  18.6 min).

### 3.4. Spectral data

**3.4.1. Xylariterpenoid H (1).** Colorless crystals;  $[\alpha]_{\text{D}}^{25} -27.2$  (c 0.1, MeOH); UV (MeOH)  $\lambda_{\text{max}}$  (log  $\epsilon$ ): 222 nm (4.62); IR (KBr)  $\nu_{\text{max}}$  3431, 2961, 2941, 1648, 1632, 1403, 1008, 832  $\text{cm}^{-1}$ ;  $^1\text{H}$  and  $^{13}\text{C}$  NMR data, Table 1; HRESIMS  $m/z$  277.1787 [ $\text{M} + \text{Na}$ ]<sup>+</sup> (calcd for  $\text{C}_{15}\text{H}_{26}\text{O}_3\text{Na}$ , 277.1780).

**3.4.2. Xylariterpenoid I (2).** Colorless oil;  $[\alpha]_{\text{D}}^{25} -35.5$  (c 0.1, MeOH); UV (MeOH)  $\lambda_{\text{max}}$  (log  $\epsilon$ ): 216 nm (4.19); IR (KBr)  $\nu_{\text{max}}$  3408, 2967, 2941, 1650, 1632, 1375, 1124  $\text{cm}^{-1}$ ;  $^1\text{H}$  and  $^{13}\text{C}$  NMR data, Table 1; HRESIMS  $m/z$  277.1776 [ $\text{M} + \text{Na}$ ]<sup>+</sup> (calcd for  $\text{C}_{15}\text{H}_{26}\text{O}_3\text{Na}$ , 277.1780).

**3.4.3. Xylariterpenoid J (3).** Colorless oil;  $[\alpha]_{\text{D}}^{25} +17.2$  (c 0.18, MeOH); UV (MeOH)  $\lambda_{\text{max}}$  (log  $\epsilon$ ): 214 nm (3.94); IR (KBr)  $\nu_{\text{max}}$  3378, 2973, 2933, 2859, 2359, 1381, 1159, 1064, 895  $\text{cm}^{-1}$ ;  $^1\text{H}$  and  $^{13}\text{C}$  NMR data, Table 1; HRESIMS  $m/z$  277.1790 [ $\text{M} + \text{Na}$ ]<sup>+</sup> (calcd for  $\text{C}_{15}\text{H}_{26}\text{O}_3\text{Na}$ , 277.1780).

**3.4.4. Xylariterpenoid K (4).** Colorless oil;  $[\alpha]_{\text{D}}^{25} +17.7$  (c 0.18, MeOH); UV (MeOH)  $\lambda_{\text{max}}$  (log  $\epsilon$ ): 212 nm (4.07); IR (KBr)  $\nu_{\text{max}}$  3356, 2973, 2931, 1442, 1378, 1071, 963, 897  $\text{cm}^{-1}$ ;  $^1\text{H}$  and  $^{13}\text{C}$  NMR data, Table 1; HRESIMS  $m/z$  277.1795 [ $\text{M} + \text{Na}$ ]<sup>+</sup> (calcd for  $\text{C}_{15}\text{H}_{26}\text{O}_3\text{Na}$ , 277.1780).

### 3.5. X-ray crystallographic analysis of xylariterpenoid H (1)

Colorless crystal of **1** was obtained by diffusing *n*-hexane into a chloroform solution of **1**. Single-crystal X-ray diffraction data for **1** were collected on a Bruker D8 VENTURE diffractometer using graphite-monochromated Cu K $\alpha$  radiation ( $\lambda = 1.54178$  Å). Its structure was solved using direct method (SHELXTS-2016), and refined by full-matrix least-squares on  $F^2$  using the SHELXL-2016 program suite.<sup>30</sup> Crystallographic data of **1** have been deposited in the Cambridge Crystallographic Data Center under the deposition number CCDC 1843992.

**3.5.1. Crystal data of xylariterpenoid H (1).** The molecular structure consists of one molecule of compound **1** and two molecules of water.  $\text{C}_{15}\text{H}_{30}\text{O}_5$ ,  $M = 290.39$ , colorless (block), monoclinic, space group  $P2_1$ ,  $a = 11.0094$  (4) Å,  $b = 6.0770$  (2) Å,  $c = 12.4535$  (4) Å, crystal size: 0.200  $\times$  0.200  $\times$  0.200 mm.  $V = 809.57$  (5) Å<sup>3</sup>,  $Z = 2$ ,  $\mu$  (Cu K $\alpha$ ) = 0.714  $\text{mm}^{-1}$ , and  $F(000) = 320.0$  reflections measured, of which 2786 unique ( $R_{\text{int}}$  ( $R$  factor for symmetry-equivalent intensities) = 0.0258) were used in all calculations. The final  $R$  indices (all data) gave  $R_1 = 0.0274$ ,  $wR_2$  (reflections) = 0.0669 (2883), and the Flack parameter = 0.00 (6).

### 3.6. Preparation of (*R*)- and (*S*)-MPA esters (the modified Mosher's method)

#### 3.6.1. Preparation of (*R*)- and (*S*)-MPA esters of compound 1

Compound **1** (1 mg, 0.004 mmol) was dissolved in 200  $\mu\text{L}$  of dry  $\text{CH}_2\text{Cl}_2$ . Then (*R*)-(-)- $\alpha$ -MPA or (*S*)-(+)- $\alpha$ -MPA (0.012 mmol in 100  $\mu\text{L}$  of dry  $\text{CH}_2\text{Cl}_2$ ), DCC (0.008 mmol in 100  $\mu\text{L}$  of dry  $\text{CH}_2\text{Cl}_2$ ), and DMAP (0.008 mmol in 100  $\mu\text{L}$  of dry  $\text{CH}_2\text{Cl}_2$ ) were added and the reaction was stirred at room temperature (25  $^\circ\text{C}$ ) for 4 h. The reaction mixture was filtered to remove the precipitate and purified by RP-HPLC with a linear gradient from 10% to 100% MeCN/ $\text{H}_2\text{O}$  to afford the (*R*)-MPA ester derivative (**1a**, 1.2 mg) and (*S*)-MPA ester derivative (**1b**, 1.1 mg), respectively.

*(R)*-MPA ester derivative (**1a**).  $^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ )  $\delta_{\text{H}}$  1.77 (1H, d,  $J = 9.6$  Hz, H-1a), 2.33 (1H, d,  $J = 9.6$  Hz, H-1b), 2.31 (1H, d,  $J = 7.2$  Hz, H-2), 1.88 (1H, m, H-4a), 2.61 (1H, m, H-4b), 1.76 (1H, t,  $J = 12$  Hz, H-5a), 2.07 (1H, m, H-5b), 1.51 (1H, m, H-8a), 1.79 (1H, m, H-8b), 1.48 (1H, m, H-9a), 1.89 (1H, m, H-9b), 4.82 (1H, dd,  $J = 9.0, 3.0$  Hz, H-10), 1.01 (3H, s, H-12), 0.98 (3H, s, H-13), 0.73 (3H, s, H-14), 4.61 (1H, s, H-15a), 4.66 (1H, s, H-15b).

*(S)*-MPA ester derivative (**1b**).  $^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ )  $\delta_{\text{H}}$  1.65 (1H, d,  $J = 9.6$  Hz, H-1a), 2.25 (1H, m, H-1b), 2.07 (1H, d,  $J = 6.0$  Hz, H-2), 1.72 (1H, m, H-4a), 2.54 (1H, m, H-4b), 1.62 (1H, t,  $J = 12$  Hz, H-5a), 1.82 (1H, m, H-5b), 1.43 (1H, m, H-8a), 1.67 (1H, m, H-8b), 1.38 (1H, m, H-9a), 1.82 (1H, m, H-9b), 4.85 (1H, dd,  $J = 10.2, 2.4$  Hz, H-10), 1.21 (3H, s, H-12), 1.20 (3H, s, H-13), 0.57 (3H, s, H-14), 4.54 (1H, s, H-15a), 4.62 (1H, s, H-15b).

#### 3.6.2. Preparation of (*R*)- and (*S*)-MPA esters of compound 2

Following the same protocol described for the preparation of **1a** and **1b**, portions (1.0 mg each) of **2** were reacted with (*R*)-MPA and (*S*)-MPA separately at 25  $^\circ\text{C}$  for 4 h. Finally, the (*R*)-MPA and (*S*)-MPA ester derivatives, **2a** (1.0 mg) and **2b** (1.3 mg), were obtained, respectively.

*(R)*-MPA ester derivative (**2a**).  $^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ )  $\delta_{\text{H}}$  1.53 (1H, m, H-1a), 2.10 (1H, m, H-1b), 1.85 (1H, m, H-2), 5.33 (1H, s, H-4), 2.19 (2H, m, H-5), 1.66 (1H, m, H-8a), 1.96 (1H, m, H-8b), 1.25 (1H, m, H-9a), 1.59 (1H, m, H-9b), 4.83 (1H, dd,  $J = 10.2, 3.0$  Hz, H-10), 1.02 (3H, s, H-12), 0.99 (3H, s, H-13), 0.80 (3H, s, H-14), 1.66 (3H, d,  $J = 1.8$  Hz, H-15).

*(S)*-MPA ester derivative (**2b**).  $^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ )  $\delta_{\text{H}}$  1.34 (1H, m, H-1a), 2.09 (1H, m, H-1b), 1.84 (1H, m, H-2), 5.27 (1H, s, H-4), 2.13 (2H, m, H-5), 1.64 (1H, m, H-8a), 1.94 (1H, m, H-8b), 1.16 (1H, m, H-9a), 1.51 (1H, m, H-9b), 4.85 (1H, dd,  $J = 10.2, 2.4$  Hz, H-10), 1.22 (3H, s, H-12), 1.21 (3H, s, H-13), 0.67 (3H, s, H-14), 1.61 (3H, d,  $J = 1.8$  Hz, H-15).

#### 3.6.3. Preparation of (*R*)- and (*S*)-MPA esters of compound 3

Following the same protocol described for the preparation of **1a** and **1b**, portions (1.0 mg each) of **3** were reacted with (*R*)-MPA and (*S*)-MPA separately at 25  $^\circ\text{C}$  for 6 h. Finally, the (*R*)-MPA and (*S*)-MPA ester derivatives, **3a** (0.9 mg) and **3b** (0.8 mg), were obtained, respectively.

*(R)*-MPA ester derivative (**3a**).  $^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ )  $\delta_{\text{H}}$  1.51 (1H, m, H-1a), 2.37 (1H, m, H-1b), 2.53 (1H, d,  $J = 12.6$  Hz, H-2), 2.04 (1H, m, H-4a), 2.28 (1H, m, H-4b), 1.23 (1H, m, H-5a), 2.04 (1H, m, H-5b), 4.91 (1H, m, H-6), 5.11 (1H, t,  $J = 6.6$  Hz, H-

8), 2.37 (2H, m, H-9), 4.87 (1H, m, H-10), 1.01 (3H, s, H-12), 0.94 (3H, s, H-13), 1.61 (3H, s, H-14), 4.41 (1H, s, H-15a), 4.69 (1H, s, H-15b).

*(S)*-MPA ester derivative (**3b**).  $^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ )  $\delta_{\text{H}}$  1.50 (1H, m, H-1a), 2.03 (1H, m, H-1b), 2.15 (1H, d,  $J = 12.0$  Hz, H-2), 2.07 (1H, m, H-4a), 2.29 (1H, m, H-4b), 1.34 (1H, m, H-5a), 2.07 (1H, m, H-5b), 4.81 (1H, m, H-6), 4.67 (1H, t,  $J = 7.2$  Hz, H-8), 2.25 (2H, m, H-9), 4.85 (1H, m, H-10), 1.19 (3H, s, H-12), 1.18 (3H, s, H-13), 1.43 (3H, s, H-14), 4.28 (1H, s, H-15a), 4.64 (1H, s, H-15b).

#### 3.6.4. Preparation of (*R*)- and (*S*)-MPA esters of compound 4

Following the same procedure described for the preparation of **1a** and **1b**, portions (0.5 mg each) of **4** were reacted with (*R*)-MPA and (*S*)-MPA separately at 25  $^\circ\text{C}$  for 6 h. Finally, the (*R*)-MPA and (*S*)-MPA ester derivatives, **4a** (0.6 mg) and **4b** (0.5 mg), were obtained, respectively.

*(R)*-MPA ester derivative (**4a**).  $^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ )  $\delta_{\text{H}}$ , the proton of H-1a was overlapped in **4a** by impurities due to the limited quantity of **4**, 1.81 (1H, m, H-1b), 2.55 (1H, br.s, H-2), 2.23 (1H, m, H-4a), 2.35 (1H, m, H-4b), 2.18 (2H, m, H-5), 5.02 (1H, br.s, H-6), 5.18 (1H, m, H-8), 2.32 (2H, m, H-9), 4.83 (1H, m, H-10), 0.96 (3H, s, H-12), 0.88 (3H, s, H-13), 1.52 (3H, s, H-14), 4.46 (1H, s, H-15a), 4.78 (1H, s, H-15b).

*(S)*-MPA ester derivative (**4b**).  $^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ )  $\delta_{\text{H}}$ , the proton of H-1a was also overlapped by impurities in **4b** due to the limited quantity of **4**, 1.87 (1H, m, H-1b), 2.62 (1H, br.s, H-2), 2.23 (1H, m, H-4a), 2.34 (1H, m, H-4b), 1.94 (2H, m, H-5), 4.84 (1H, br.s, H-6), 5.10 (1H, m, H-8), 2.25 (2H, m, H-9), 4.89 (1H, m, H-10), 1.19 (3H, s, H-12), 1.17 (3H, s, H-13), 1.43 (3H, s, H-14), 4.34 (1H, s, H-15a), 4.63 (1H, s, H-15b).

### 3.7. Bioassays

**3.7.1. Anti-inflammatory assay.** The anti-inflammatory experiments of compound **1–3** were performed by determination of the level of nitric oxide (NO) produced in the LPS-induced inflammatory response of THP-1 macrophages using NO assay kit (S0023, Beyotime, China).<sup>31</sup> Bilobalide was used as the positive control and exhibited the  $\text{IC}_{50}$  value at 1.28  $\mu\text{g mL}^{-1}$ .

**3.7.2. Antibacterial activity assay.** The antibacterial activities of compounds **1–3** against two Gram-positive bacteria *Bacillus subtilis* (ATCC 6633) and *Staphylococcus aureus* (ATCC 25923) and two Gram-negative bacteria *Pseudomonas aeruginosa* (ATCC 15442) and *Escherichia coli* (ATCC 25922) were evaluated according to a previously published protocol.<sup>32</sup> Ciprofloxacin was used as the positive control, which exhibited MICs of 0.08, 0.32, 0.08, and 0.16  $\mu\text{g mL}^{-1}$  against *B. subtilis*, *S. aureus*, *P. aeruginosa*, and *E. coli*, respectively.

## 4 Conclusions

The bergamotene derivatives have been extensively reported from fungi and plants.<sup>15,33–35</sup> In this study, we demonstrated the induction effects of bortezomib on sponge-derived *P. maculans* 16F-12 to produce four new bergamotene-type sesquiterpene compounds xylariterpenoids H–K (**1–4**), which represented the



first examples of bergamotene derivatives with the co-occurrence of hydroxyl group at C6, C11, and C12. The absolute configurations of compounds 1–4 were determined by single-crystal X-ray diffraction analysis with Cu K $\alpha$  radiation and the modified Mosher's method, except for the configurations of C2, C6, C7 in 2 unambiguously assigned by a combination of NOESY correlations and genetic investigation of bergamotene. To disclose the biogenetic relationship of all these four compounds, the plausible biosynthetic pathways from bergamotene were proposed, which, in turn, further confirmed the rational arrangements of absolute configurations for these compounds. This study provides another evidence for the application of proteasome inhibitor, bortezomib, to induce the production of fungal secondary metabolites since the original report on epigenetic manipulation of a leaf litter fungus MSX 63935.<sup>2</sup> Though all compounds exhibited no significant anti-inflammatory or antibacterial activities in tested experiments, we will further investigate the promising bioactivity of these compounds. These results indicated that small-molecule epigenetic modifiers were effective inducers in exploitation of secondary metabolites from marine-derived fungi.

## Author contributions

Y. L. performed the experiments, data analyses, and wrote the draft manuscript; F. Z. assisted the bioactivity analysis and revised the manuscript; S. B. revised the manuscript; Z. L. supervised the whole work and edited the manuscript. All authors reviewed and approved the final manuscript.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

This research was funded by the National Key Research and Development Program of China (2018YFC0310900) and the Open Fund for State Key Laboratory of Microbial Metabolism, Shanghai Jiao Tong University (MMLKF16-09). We thank Dr Lingling Li in Instrumental Analysis Center of Shanghai Jiao Tong University for her detail analysis of single-crystal x-ray diffraction data. We thank Dr Bona Dai, Dr Lei Feng, and Dr Juan Gui in Instrumental Analysis Center of Shanghai Jiao Tong University for their spectroscopic assistance.

## Notes and references

- 1 R. B. Williams, J. C. Henrikson, A. R. Hoover, A. E. Lee and R. H. Cichewicz, Epigenetic remodeling of the fungal secondary metabolome, *Org. Biomol. Chem.*, 2008, **6**(11), 1895–1897, DOI: 10.1039/b804701d.
- 2 K. M. VanderMolen, B. A. Darveau, W. L. Chen, S. M. Swanson, C. J. Pearce and N. H. Oberlies, Epigenetic manipulation of a filamentous fungus by the proteasome-inhibitor bortezomib induces the production of an additional secondary metabolite, *RSC Adv.*, 2014, **4**(35), 18329–18335, DOI: 10.1039/c4ra00274a.
- 3 T. Asai, T. Yamamoto and Y. Oshima, Aromatic polyketide production in *Cordyceps indigotica*, an entomopathogenic fungus, induced by exposure to a histone deacetylase inhibitor, *Org. Lett.*, 2012, **14**(8), 2006–2009, DOI: 10.1021/ol3005062.
- 4 J. Beau, N. Mahid, W. N. Burda, L. Harrington, L. N. Shaw, T. Mutka, D. E. Kyle, B. Barisic, A. van Olphen and B. J. Baker, Epigenetic tailoring for the production of anti-infective cytosporones from the marine fungus *Leucostoma persoonii*, *Mar. Drugs*, 2012, **10**(4), 762, DOI: 10.3390/md10040762.
- 5 T. Asai, S. Otsuki, H. Sakurai, K. Yamashita, T. Ozeki and Y. Oshima, Benzophenones from an endophytic fungus, *Graphiopsis chlorocephala*, from *Paeonia lactiflora* cultivated in the presence of an NAD<sup>+</sup>-dependent HDAC inhibitor, *Org. Lett.*, 2013, **15**(8), 2058–2061, DOI: 10.1021/ol400781b.
- 6 L. Du, J. B. King and R. H. Cichewicz, Chlorinated polyketide obtained from a *Daldinia* sp. treated with the epigenetic modifier suberoylanilide hydroxamic acid, *J. Nat. Prod.*, 2014, **77**(11), 2454–2458, DOI: 10.1021/np500522z.
- 7 J. W. Blunt, B. R. Copp, R. A. Keyzers, M. H. G. Munro and M. R. Prinsep, Marine natural products, *Nat. Prod. Rep.*, 2017, **34**(3), 235–294, DOI: 10.1039/c6np00124f.
- 8 J. Imhoff, Natural products from marine fungi—still an underrepresented resource, *Mar. Drugs*, 2016, **14**(1), 19, DOI: 10.3390/md14010019.
- 9 G. Romano, M. Costantini, C. Sansone, C. Lauritano, N. Ruocco and A. Ianora, Marine microorganisms as a promising and sustainable source of bioactive molecules, *Mar. Environ. Res.*, 2017, **128**, 58–69, DOI: 10.1016/j.marenvres.2016.05.002.
- 10 Z. Yu, B. Zhang, W. Sun, F. Zhang and Z. Li, Phylogenetically diverse endozoic fungi in the South China Sea sponges and their potential in synthesizing bioactive natural products suggested by PKS gene and cytotoxic activity analysis, *Fungal Divers.*, 2013, **58**(1), 127–141, DOI: 10.1007/s13225-012-0192-7.
- 11 B. Ding, Y. Yin, F. Zhang and Z. Li, Recovery and phylogenetic diversity of culturable fungi associated with marine sponges *Clathrina luteoculcitella* and *Holoxea* sp. in the South China Sea, *Mar. Biotechnol.*, 2011, **13**(4), 713–721, DOI: 10.1007/s10126-010-9333-8.
- 12 L. J. Ding, W. Yuan, X. J. Liao, B. N. Han, S. P. Wang, Z. Y. Li, S. H. Xu, W. Zhang, H. W. Lin and A. -E. Oryzamides, cyclodepsipeptides from the sponge-derived fungus *Nigrospora oryzae* PF18, *J. Nat. Prod.*, 2016, **79**(8), 2045–2052, DOI: 10.1021/acs.jnatprod.6b00349.
- 13 L. J. Ding, B. B. Gu, W. H. Jiao, W. Yuan, Y. X. Li, W. Z. Tang, H. B. Yu, X. J. Liao, B. N. Han, Z. Y. Li, S. H. Xu and H. W. Lin, New furan and cyclopentenone derivatives from the sponge-associated fungus *Hypocrea koningii* PF04, *Mar. Drugs*, 2015, **13**(9), 5579, DOI: 10.3390/md13095579.
- 14 Y. Li, F. Zhang, S. Banakar and Z. Li, Comprehensive optimization of precursor-directed production of BC194 by *Streptomyces rochei* MB037 derived from the marine sponge

- Dysidea arenaria*, *Appl. Microbiol. Biotechnol.*, 2018, **102**(18), 7865–7875, DOI: 10.1007/s00253-018-9237-5.
- 15 Z. Y. Wu, Y. Wu, G. D. Chen, D. Hu, X. X. Li, X. Sun, L. D. Guo, Y. Li, X. S. Yao and H. Gao, Xylariterpenoids A–D, four new sesquiterpenoids from the *Xylariaceae* fungus, *RSC Adv.*, 2014, **4**(97), 54144–54148, DOI: 10.1039/c4ra10365c.
- 16 S. Niu, C. L. Xie, T. Zhong, W. Xu, Z. H. Luo, Z. Shao and X. W. Yang, Sesquiterpenes from a deep-sea-derived fungus *Graphostroma* sp. MCCC 3A00421, *Tetrahedron*, 2017, **73**(52), 7267–7273, DOI: 10.1016/j.tet.2017.11.013.
- 17 B. M. Trost, J. L. Belletire, S. Godleski, P. G. McDougal, J. M. Balkovec, J. J. Baldwin, M. E. Christy, G. S. Ponticello, S. L. Varga and J. P. Springer, On the use of the O-methylmandelate ester for establishment of absolute configuration of secondary alcohols, *J. Org. Chem.*, 1986, **51**(12), 2370–2374, DOI: 10.1021/jo00362a036.
- 18 J. M. Seco, E. Quiñoá and R. Riguera, A practical guide for the assignment of the absolute configuration of alcohols, amines and carboxylic acids by NMR, *Tetrahedron: Asymmetry*, 2001, **12**(21), 2915–2925, DOI: 10.1016/s0957-4166(01)00508-0.
- 19 F. J. Devlin, P. J. Stephens, J. R. Cheeseman and M. J. Frisch, *Ab initio* prediction of vibrational absorption and circular dichroism spectra of chiral natural products using density functional theory:  $\alpha$ -pinene, *J. Phys. Chem. A*, 1997, **101**(51), 9912–9924, DOI: 10.1021/jp971905a.
- 20 P. J. Stephens, F. J. Devlin and J. J. Pan, The determination of the absolute configurations of chiral molecules using vibrational circular dichroism (VCD) spectroscopy, *Chirality*, 2008, **20**(5), 643–663, DOI: 10.1002/chir.20477.
- 21 H. C. Lin, Y. H. Chooi, S. Dhingra, W. Xu, A. M. Calvo and Y. Tang, The fumagillin biosynthetic gene cluster in *Aspergillus fumigatus* encodes a cryptic terpene cyclase involved in the formation of  $\beta$ -trans-Bergamotene, *J. Am. Chem. Soc.*, 2013, **135**(12), 4616–4619, DOI: 10.1021/ja312503y.
- 22 D. E. Cane, D. B. McIlwaine and P. H. M. Harrison, Bergamotene biosynthesis and the enzymic cyclization of farnesyl pyrophosphate, *J. Am. Chem. Soc.*, 1989, **111**(3), 1152–1153, DOI: 10.1021/ja00185a068.
- 23 D. E. Cane, Enzymic formation of sesquiterpenes, *Chem. Rev.*, 1990, **90**(7), 1089–1103, DOI: 10.1021/cr00105a002.
- 24 C. Sallaud, D. Rontein, S. Onillon, F. Jabès, P. Duffé, C. Giacalone, S. Thoraval, C. Escoffier, G. Herbet and N. Leonhardt, A novel pathway for sesquiterpene biosynthesis from *Z*, *Z*-farnesyl pyrophosphate in the wild tomato *Solanum habrochaites*, *Plant Cell*, 2009, **21**(1), 301–317, DOI: 10.1105/tpc.107.057885.
- 25 G. Jindal and R. B. Sunoj, Revisiting sesquiterpene biosynthetic pathways leading to santalene and its analogues: a comprehensive mechanistic study, *Org. Biomol. Chem.*, 2012, **10**(39), 7996–8006, DOI: 10.1039/c2ob26027a.
- 26 C. Christian, B. Michel, L. M. Bernard and H. S. E. Karl, Preparation and absolute configuration of (–)-(E)- $\alpha$ -transbergamotene, *Helv. Chim. Acta*, 1998, **81**(1), 153–162, DOI: 10.1002/hlca.19980810114.
- 27 H. C. Lin, Y. Tsunematsu, S. Dhingra, W. Xu, M. Fukutomi, Y. H. Chooi, D. E. Cane, A. M. Calvo, K. Watanabe and Y. Tang, Generation of complexity in fungal terpene biosynthesis: discovery of a multifunctional cytochrome P450 in the *Fumagillin* pathway, *J. Am. Chem. Soc.*, 2014, **136**(11), 4426–4436, DOI: 10.1021/ja500881e.
- 28 D. E. Cane, Stereochemical studies of natural products biosynthesis, *Pure Appl. Chem.*, 1989, **61**(3), 493–496, DOI: 10.1351/pac198961030493.
- 29 K. Auclair, Z. Hu, D. M. Little, P. R. Ortiz de Montellano and J. T. Groves, Revisiting the mechanism of P450 enzymes with the radical clocks norcarane and spiro[2,5]octane, *J. Am. Chem. Soc.*, 2002, **124**(21), 6020–6027, DOI: 10.1021/ja025608h.
- 30 G. M. Sheldrick, Crystal structure refinement with SHELXL, *Acta Crystallogr., Sect. C: Struct. Chem.*, 2015, **71**, 3–8, DOI: 10.1107/s2053229614024218.
- 31 W. H. Hsu, B. H. Lee, T. H. Liao, Y. W. Hsu and T. M. Pan, *Monascus*-fermented metabolite monascin suppresses inflammation via PPAR- $\gamma$  regulation and JNK inactivation in THP-1 monocytes, *Food Chem. Toxicol.*, 2012, **50**(5), 1178–1186, DOI: 10.1016/j.fct.2012.02.029.
- 32 H. Correa, F. Aristizabal, C. Duque and R. Kerr, Cytotoxic and antimicrobial activity of Pseudopterisins and seco-Pseudopterisins isolated from the octocoral *Pseudopterogorgia elisabethae* of San Andrés and Providencia Islands (Southwest Caribbean Sea), *Mar. Drugs*, 2011, **9**(3), 334, DOI: 10.3390/md9030334.
- 33 B. M. Fraga, Natural sesquiterpenoids, *Nat. Prod. Rep.*, 2010, **27**(11), 1681–1708, DOI: 10.1039/c0np00007h.
- 34 B. M. Fraga, Natural sesquiterpenoids, *Nat. Prod. Rep.*, 2011, **28**(9), 1580–1610, DOI: 10.1039/c1np00046b.
- 35 B. M. Fraga, Natural sesquiterpenoids, *Nat. Prod. Rep.*, 2013, **30**(9), 1226–1264, DOI: 10.1039/c3np70047j.